This study investigates locally advanced pancreatic cancer. The purpose of this study is to evaluate the effectiveness and safety of an investigational medication combined with the AG regimen as a conversion therapy.
The study focuses on assessing how well the investigational medication works and its safety. It evaluates different aspects like response rates and quality of life changes.
- Who can participate: Adults aged 18 to 75 with locally advanced pancreatic cancer may participate. Key eligibility includes confirmed pancreatic ductal adenocarcinoma and no prior antitumor therapy.
- Study details: Participants will receive the investigational medication combined with other treatments. A placebo is not used in this study.